Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9

Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9

SLC26A9, a constitutively active Cl<sup>−</sup> transporter, has gained interest over the past years as a relevant disease modifier in several respiratory disorders including Cystic Fibrosis (CF), asthma, and non-CF bronchiectasis. SLC26A9 contributes to epithelial Cl<sup>−</sup...

Full description

Bibliographic Details
Main Authors: Madalena C. Pinto, Margarida C. Quaresma, Iris A. L. Silva, Violeta Railean, Sofia S. Ramalho, Margarida D. Amaral
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:International Journal of Molecular Sciences
Subjects:
SLC26A9
anion channels
CFTR
Cl<sup>−</sup> secretion
Cystic Fibrosis
Online Access:https://www.mdpi.com/1422-0067/22/23/13064

Internet

https://www.mdpi.com/1422-0067/22/23/13064

Similar Items